Heather E Whitson1, Alice M Arnold2, Laura M Yee2, Kenneth J Mukamal3, Jorge R Kizer4, Luc Djousse3, Joachim H Ix5, David Siscovick6, Russell P Tracy7, Stephen M Thielke8, Calvin Hirsch9, Anne B Newman10, Susan Zieman11. 1. Department of Medicine, Duke University, Durham, North Carolina. Durham VA Medical Center, GRECC, Durham, North Carolina. heather.whitson@duke.edu. 2. Department of Biostatistics, University of Washington, Seattle. 3. Department of Medicine, Harvard Medical School, Boston, Massachusetts. 4. Department of Medicine, and Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York. 5. Departments of Medicine & Prevention and Family Medicine, University of California, San Diego. Nephrology Section, Veterans Affairs San Diego Healthcare System, California. 6. Department of Medicine, University of Washington, Seattle. 7. Department of Pathology, University of Vermont, Colchester. 8. Puget Sound VA Medical Center, Seattle, Wahington. Department of Psychiatry, University of Washington, Seattle. 9. Department of Medicine, University of California Davis. 10. Department of Epidemiology, University of Pittsburgh, Pennsylvania. 11. National Institute on Aging, National Institutes of Health, Bethesda, Maryland.
Abstract
BACKGROUND: Advanced glycation endproducts are biologically active compounds that accumulate in disordered metabolism and normal aging. Carboxymethyl-lysine (CML), a ubiquitous human advanced glycation endproduct, has been associated with age-related conditions and mortality. Our objective was to ascertain the relationship between CML and geriatric outcomes (disability and frailty) in a large cohort of older men and women. METHODS: In 1996-1997, serum CML was measured in 3,373 Cardiovascular Health Study participants (mean age 78.1 ± 4.8 years). Disability, defined as difficulty in any of six activities of daily living, was assessed every 6-12 months for 14 years. Frailty was defined according to five standard criteria at the 1996-1997 visit. Cox proportional hazard models estimated the relationship between CML and incident disability (N = 2,643). Logistic regression models estimated the relationship between CML and prevalent frailty. RESULTS: Adjusting for multiple potential confounders, higher CML was associated with incident disability (hazard ratio per standard deviation [225 ng/mL] increase: 1.05, 95% CI 1.01-1.11). In men, odds of frailty increased with higher CML values (odds ratio = 1.30 per standard deviation, 95% CI 1.14-1.48), but the relationship was attenuated by adjustment for cognitive status, kidney function, and arthritis. CML was not associated with frailty in women. CONCLUSIONS: Higher serum CML levels in late life are associated with incident disability and prevalent frailty. Further work is needed to understand CML's value as a risk stratifier, biomarker, or target for interventions that promote healthy aging.
BACKGROUND: Advanced glycation endproducts are biologically active compounds that accumulate in disordered metabolism and normal aging. Carboxymethyl-lysine (CML), a ubiquitous human advanced glycation endproduct, has been associated with age-related conditions and mortality. Our objective was to ascertain the relationship between CML and geriatric outcomes (disability and frailty) in a large cohort of older men and women. METHODS: In 1996-1997, serum CML was measured in 3,373 Cardiovascular Health Study participants (mean age 78.1 ± 4.8 years). Disability, defined as difficulty in any of six activities of daily living, was assessed every 6-12 months for 14 years. Frailty was defined according to five standard criteria at the 1996-1997 visit. Cox proportional hazard models estimated the relationship between CML and incident disability (N = 2,643). Logistic regression models estimated the relationship between CML and prevalent frailty. RESULTS: Adjusting for multiple potential confounders, higher CML was associated with incident disability (hazard ratio per standard deviation [225 ng/mL] increase: 1.05, 95% CI 1.01-1.11). In men, odds of frailty increased with higher CML values (odds ratio = 1.30 per standard deviation, 95% CI 1.14-1.48), but the relationship was attenuated by adjustment for cognitive status, kidney function, and arthritis. CML was not associated with frailty in women. CONCLUSIONS: Higher serum CML levels in late life are associated with incident disability and prevalent frailty. Further work is needed to understand CML's value as a risk stratifier, biomarker, or target for interventions that promote healthy aging.
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Bente K Kilhovd; Auni Juutilainen; Seppo Lehto; Tapani Rönnemaa; Peter A Torjesen; Kåre I Birkeland; Tore J Berg; Kristian F Hanssen; Markku Laakso Journal: Arterioscler Thromb Vasc Biol Date: 2005-02-03 Impact factor: 8.311
Authors: Richard D Semba; Luigi Ferrucci; Kai Sun; Justine Beck; Mansi Dalal; Ravi Varadhan; Jeremy Walston; Jack M Guralnik; Linda P Fried Journal: Aging Clin Exp Res Date: 2009-04 Impact factor: 3.636
Authors: Alice M Arnold; Anne B Newman; Mary Cushman; Jingzhong Ding; Stephen Kritchevsky Journal: J Gerontol A Biol Sci Med Sci Date: 2009-04-22 Impact factor: 6.053
Authors: Isha Agarwal; Nicole L Glazer; Eddy Barasch; Luc Djousse; John S Gottdiener; Joachim H Ix; Jorge R Kizer; Eric B Rimm; David S Siscovick; George L King; Ken J Mukamal Journal: Metabolism Date: 2015-07-21 Impact factor: 8.694
Authors: Hans Drenth; Sytse Zuidema; Steven Bunt; Ivan Bautmans; Cees van der Schans; Hans Hobbelen Journal: Eur Rev Aging Phys Act Date: 2016-03-04 Impact factor: 3.878
Authors: Helen Ebert; Maria Elena Lacruz; Alexander Kluttig; Andreas Simm; Karin Halina Greiser; Daniel Tiller; Nadja Kartschmit; Rafael Mikolajczyk Journal: BMC Geriatr Date: 2019-11-04 Impact factor: 3.921
Authors: Petra Bůžková; Joshua I Barzilay; Howard A Fink; John A Robbins; Jane A Cauley; Joachim H Ix; Kenneth J Mukamal Journal: Clin Kidney J Date: 2019-03-21